Abstract:Objective: To analyze the treatment and prognosis of patients with International Federation of Gynecology and Obstetrics (FIGO) 2018 stage Ⅲc cervical squamous cell carcinoma. Methods: A total of 488 patients at Zhejiang Cancer Hospital between May, 2013 to May, 2015 were enrolled. The clinical characteristics and prognosis were compared according to the treatment mode (surgery combined with postoperative chemoradiotherapy vs radical concurrent chemoradiotherapy). The median follow-up time was (96±12) months ( range time from 84 to 108 months). Results: (1) The data were divided into surgery combined with chemoradiotherapy group (surgery group) and concurrent chemoradiotherapy group (radiotherapy group), including 324 cases in the surgery group and 164 cases in the radiotherapy group. There were significant differences in Eastern Cooperation Oncology Group (ECOG) score, FIGO 2018 stage, large tumors (≥4 cm), total treatment time and total treatment cost between the two groups (all P<0.01). (2) Prognosis: ① for stage Ⅲc1 patients, there were 299 patients in the surgery group with 250 patients survived (83.6%). In the radiotherapy group, 74 patients survived (52.9%). The difference of survival rates between the two groups was statistically significant (P<0.001). For stage Ⅲc2 patients, there were 25 patients in surgery group with 12 patients survived (48.0%). In the radiotherapy group, there were 24 cases, 8 cases survived, the survival rate was 33.3%. There was no significant difference between the two groups (P=0.296). ② For patients with large tumors (≥4 cm) in the surgery group, there were 138 patients in the Ⅲc1 group with 112 patients survived (81.2%); in the radiotherapy group, there were 108 cases with 56 cases survived (51.9%). The difference between the two groups was statistically significant (P<0.001). Large tumors accounted for 46.2% (138/299) vs 77.1% (108/140) in the surgery group and radiotherapy group. The difference between the two groups was statistically significant (P<0.001). Further stratified analysis, a total of 46 patients with large tumors of FIGO 2009 stage Ⅱb in the radiotherapy group were extracted, and the survival rate was 67.4%, there was no significant difference compared with the surgery group (81.2%; P=0.052). ③ Of 126 patients with common iliac lymph node, 83 patients survived, with a survival rate of 65.9% (83/126). In the surgery group, 48 patients survived and 17 died, with a survival rate of 73.8%. In the radiotherapy group, 35 patients survived and 26 died, with a survival rate of 57.4%. There were no significant difference between the two groups (P=0.051). (3) Side effects: the incidence of lymphocysts and intestinal obstruction in the surgery group were higher than those in the radiotherapy group, and the incidence of ureteral obstruction and acute and chronic radiation enteritis were lower than those in the radiotherapy group, and there were statistically significant differences (all P<0.01). Conclusions: For stage Ⅲc1 patients who meet the conditions for surgery, surgery combined with postoperative adjuvant chemoradiotherapy and radical chemoradiotherapy are acceptable treatment methods regardless of pelvic lymph node metastasis (excluding common iliac lymph node metastasis), even if the maximum diameter of the tumor is ≥4 cm. For patients with common iliac lymph node metastasis and stage Ⅲc2, there is no significant difference in the survival rate between the two treatment methods. Based on the duration of treatment and economic considerations, concurrent chemoradiotherapy is recommended for the patients.

A Surgery-based Comprehensive Treatment Improved Prognosis in Patients with Stage IIIC Cervical Squamous Carcinoma: A Single Center Retrospective Study

[Analysis of Prognostic Factors in Patients with Cervical Squamous Cell Carcinoma of Stage Ib and IIa].

Prognostic analysis of stage IIIC1p cervical cancer patients

A Retrospective Analysis Of Prognostic Factors In Patients With Cervical Non-Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy

Prognosis of Stage III Cervical Cancer: a Two-Way Outcome Study.

Clinical Outcomes and Prognostic Factors in Stage III C Cervical Cancer Patients Treated with Radical Radiotherapy or Radiochemotherapy

Effect of different treatment modalities on the prognosis of patients with stage IIIC cervical cancer

Analysis of Prognostic Factors of Ⅰ A～ Ⅱ B Squamous Carcinoma of the Cervix

[Treatment and prognosis analysis of 488 patients with FIGO 2018 stage Ⅲc squamous cervical cancer].

Clinical Outcomes and Prognostic Factors of Patients with Epithelial Ovarian Cancer Subjected to First-Line Treatment: a Retrospective Study of 251 Cases

The Clinical and Prognostic Analysis of 363 Cases of Stage ⅠB1 ～ ⅡA2 Cervical Cancer

Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients with Stage IIIC Cervical Cancer

Clinical and Pathological Factors Related to the Prognosis of Chinese Patients with Stage Ⅰb to Ⅱb Cervical Cancer

Development And Validation Of A Surgical-Pathologic Staging And Scoring System For Cervical Cancer

Prognostic Factors and Local Treatment Modalities of Small-Cell Carcinoma of the Cervix: an Analysis According to the International Federation of Gynecology and Obstetrics Stage

Prognostic Evaluation of Postoperative Adjuvant Therapy for Operable Cervical Cancer: 10 Years' Experience of National Cancer Center in China.

A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System

Outcome of International Federation of Gynecology and Obstetrics Stage IIb Cervical Cancer from 2003 to 2012: an Evaluation of Treatments and Prognosis: a Retrospective Study.

Validation of the prognostic value of the 2018 FIGO stage IIIC in patients with cervical cancer

Clinical Results and Prognostic Factors of Patients with Locally Advanced Cervical Carcinoma Treated with Neoadjuvant Therapy Followed by Radical Hysterectomy : a Retrospective Study of 182 Patients

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review